Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05347771 · ClinicalTrials.gov registry record · Phase 2
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
A Phase 2 study of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 8
- Study locations
NCT05347771: Active Phase 2 study of Asthma, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT05347771 is a Phase 2 study of Asthma that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05347771, a Phase 2 study of Asthma, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
Primary Outcome
Asthma exacerbation defined as a prescription of a course of systemic steroids by a clinician or initiation of a course of systemic steroids by a participant to prevent a serious asthma outcome. If a participant initiates and completes a course of systemic steroids without clinician involvement, this course will be counted only if it meets the following dosage: the course for prednisone, prednisolone, or methylprednisolone will be at least 20 mg daily dose for 3 of 5 consecutive days. The course
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (8)
New York
- Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute - New York
- Columbia University Medical Center: Division of Pediatric Pulmonology - New York
Colorado
- Children's Hospital Colorado: Allergy Program - Aurora
District of Columbia
- Children's National Medical Center: Children's Research Institute - Washington D.C.
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology - Chicago
Massachusetts
- Boston Children's Hospital: Department of Immunology - Boston
Missouri
- Washington University at St. Louis - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center: Asthma Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2022-05-04 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 2 |
What the registry record for NCT05347771 still lists
NCT05347771 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05347771 lists 8 locations in 7 states (New York, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05347771 about?
NCT05347771 is a clinical study titled "Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents". This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.
What is the current status of trial NCT05347771?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2022-05-04. Estimated completion is 2027-03-15.
What conditions does trial NCT05347771 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT05347771?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05347771?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05347771 being conducted?
This trial has 8 study locations across Colorado, District of Columbia, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05347771's enrollment target sits among peer trials
240 140th of 374 higher than 234 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI